Enliven Therapeutics Inc (NASDAQ: ELVN) kicked off on Tuesday, down -7.81% from the previous trading day, before settling in for the closing price of $17.93. Over the past 52 weeks, ELVN has traded in a range of $13.30-$25.37.
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.02%. While this was happening, its average annual earnings per share was recorded 11.35%. With a float of $43.29 million, this company’s outstanding shares have now reached $59.26 million.
Let’s determine the extent of company efficiency that accounts for 62 employees.
Enliven Therapeutics Inc (ELVN) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Enliven Therapeutics Inc is 27.06%, while institutional ownership is 77.97%. The most recent insider transaction that took place on Dec 19 ’25, was worth 84,206. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 5,000 shares at a rate of $16.84, taking the stock ownership to the 897,688 shares. Before that another transaction happened on Dec 19 ’25, when Company’s Officer proposed sale 5,000 for $16.68, making the entire transaction worth $83,400.
Enliven Therapeutics Inc (ELVN) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.46 earnings per share (EPS), higher than consensus estimate (set at -0.52) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.61% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Take a look at Enliven Therapeutics Inc’s (ELVN) current performance indicators. Last quarter, stock had a quick ratio of 32.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.97 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Looking closely at Enliven Therapeutics Inc (NASDAQ: ELVN), its last 5-days average volume was 0.92 million, which is a jump from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 29.76%.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 9.18%, which indicates a significant decrease from 12.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.46 in the past 14 days, which was higher than the 1.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.24, while its 200-day Moving Average is $19.86. However, in the short run, Enliven Therapeutics Inc’s stock first resistance to watch stands at $17.45. Second resistance stands at $18.37. The third major resistance level sits at $18.85. If the price goes on to break the first support level at $16.04, it is likely to go to the next support level at $15.56. Now, if the price goes above the second support level, the third support stands at $14.64.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
The company with the Market Capitalisation of 981.01 million has total of 59,347K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -89,020 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -20,150 K.
